Loading clinical trials...

e-CHEC-uP: Scaling up an Efficacious Cancer Screening Intervention for Women With Limited English | Clinical Trials | Clareo Health

COMPLETEDNA

e-CHEC-uP: Scaling up an Efficacious Cancer Screening Intervention for Women With Limited English

NCT03726619•Johns Hopkins University

View on ClinicalTrials.gov

Summary

This research is being done to learn more about whether or not Korean American women will improve the screening practices for breast and cervical cancer if subjects receive education and follow-up from community health workers. The education materials may be given via online or in-person. Primary Hypothesis: e-CHEC-uP will be as efficacious as the original CHEC-uP in promoting mammogram and Pap test screening among Korean immigrant women (KIW) at 6 months. Objectives: (1) To develop a web-based platform of the health literacy education component of the original CHEC-uP intervention; (2) To evaluate the acceptability and usability of the web version of the health literacy education in a user testing sample of 10 KIW; and (3) To conduct a pilot study to test the preliminary efficacy of the web version of CHEC-uP (e-CHEC-uP) in 40 KIW.

Detailed Description

e-CHEC-uP stands for e-Community based breast and cervical cancer control education program.

Eligibility

Age

21 - 65 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•Age 21-65 years
•Self-identified as a Korean American woman
•Overdue for a mammogram (40-65 years of age only) or a Pap test\*\*
•Able to read and write Korean or English
•Willing to provide written consent to allow the researchers to audit medical records for mammography and Pap test use

Exclusion Criteria

•A cancer diagnosis
•Being pregnant
•An acute and/or terminal condition (e.g., life expectancy of less than 6 months or last cancer treatment within the last 5 years)
•Psychiatric diagnosis (e.g., schizophrenia or cognitive impairment) or other conditions that preclude participation in the study activities
•Had undergone a hysterectomy

Locations (1)

Johns Hopkins University

Baltimore, Maryland, United States

Key Dates

Start Date

July 14, 2019

Primary Completion Date

August 17, 2020

Completion Date

August 17, 2020

Last Updated

August 19, 2020

Enrollment

ACTUAL participants

Conditions

Breast CancerCervical Cancer

Interventions

e-CHEC-uP

BEHAVIORAL

CHEC-uP

BEHAVIORAL

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

NCT05673200

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+2 more

View study

RECRUITINGPHASE1

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

NCT05372640

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+6 more

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 19, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

e-CHEC-uP: Scaling up an Efficacious Cancer Screening Intervention for Women With Limited English

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer